Viatris Inc Ord Shs Stock Price, News & Analysis

On December 1, 2021, Viatris (NASDAQ: VTRS) announced that the U.S. Court of Appeals affirmed a prior ruling that invalidated Biogen's Tecfidera patent for lack of written description. This decision supports Viatris' launch of a generic version of Tecfidera in August 2020, facilitating greater access to multiple sclerosis treatments. CEO Michael Goettler expressed satisfaction with the ruling, highlighting Viatris' commitment to improving patient access to affordable medications.

Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 7:30 a.m. ET. Executives Michael Goettler, Rajiv Malik, and Sanjeev Narula will engage in a discussion regarding company insights. Investors can access the live webcast at investor.viatris.com. An archived version will also be available post-event. Viatris aims to empower global healthcare access and provides over 1,400 approved molecules in diverse therapeutic areas.

Viatris (NASDAQ: VTRS) and Biocon Biologics announced the U.S. launch of interchangeable biosimilars SEMGLEE^® (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) to aid in controlling high blood sugar for diabetes patients. Both products are available in various forms and can be substituted for the reference brand LANTUS^®. Viatris emphasizes their commitment to improving access to affordable healthcare through a range of patient assistance programs, including copay and cash-pay options, effective from 2022.

Viatris Inc. (NASDAQ: VTRS) announced a $1 million donation to SBP, focusing on the Got Your Back Fund, which supports low-to-moderate income U.S. veterans in disaster recovery. This partnership aims to address housing instability exacerbated by COVID-19 by providing rebuilt and modified homes for veterans with disabilities. Viatris has contributed over $3 million to SBP since 2016, reinforcing its commitment to social support. The CEO emphasized the importance of funding in disaster recovery, particularly for veterans, while SBP's CEO expressed gratitude for Viatris's support in easing access to assistance.

Pittsburgh, Nov. 8, 2021 - Viatris reported Q3 2021 financial results with total revenues of $4.54 billion, U.S. GAAP net earnings of $312 million, and adjusted EBITDA of $1.70 billion. The company raised its 2021 financial guidance, projecting total revenues between $17.70 billion and $17.90 billion. Free cash flow is now expected to range between $2.40 billion and $2.60 billion. Viatris returned $266 million to shareholders in dividends and reduced debt by $1.9 billion in the first three quarters. A virtual investor event is scheduled for January 7, 2022.

On October 20, 2021, Viatris Inc. (NASDAQ: VTRS) announced that its interchangeable biosimilar Semglee^® (insulin glargine-yfgn) will be listed as a preferred insulin brand on Express Scripts' National Preferred Formulary, impacting over 28 million lives. This decision aims to enhance patient access to affordable insulin, with both Semglee and its authorized counterpart set to launch before year-end 2021. The formulary change will take effect on January 1, 2022, promoting greater adoption of insulin among patients with diabetes.

Viatris Inc. (NASDAQ: VTRS) will release its third quarter 2021 financial results on November 8 before the U.S. market opens. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will host a webcast at 10 a.m. ET on the same day to discuss the results. Investors can access the live webcast via investor.viatris.com or by phone. Viatris, formed in November 2020, operates globally and has a portfolio of over 1,400 approved medicines.

Viatris Inc. (NASDAQ: VTRS) has been ranked fifth on Fortune's Change the World list, recognizing its positive societal impact through healthcare initiatives. The company was acknowledged for expanding access to HIV medications in low- and middle-income countries via public-private partnerships. Key achievements include introducing a low-cost dolutegravir regimen for $75 per year and a pediatric version at a 75% reduced cost, promoting affordable treatment. Viatris serves over 40% of global HIV patients and emphasizes its commitment to social responsibility and innovative healthcare solutions.

Viatris reported Q2 2021 revenues of $4.58 billion with a GAAP net loss of $279 million. Adjusted EBITDA stood at $1.68 billion, while net cash from operating activities was $559 million and free cash flow reached $470 million. The company raised its full-year guidance: total revenues are now expected to be between $17.5 billion and $17.9 billion, adjusted EBITDA between $6.15 billion and $6.45 billion, and free cash flow between $2.2 billion and $2.4 billion. Additionally, a quarterly dividend of $0.11 per share was declared, and $1.15 billion of debt was paid down in H1 2021.